Mechanisms in the loss of capillaries in systemic sclerosis: Angiogenesis versus vasculogenesis

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 A, 2010, Pages 1241-1254

  Manetti, Mirko ^a   Guiducci, Serena ^a   Ibba Manneschi, Lidia ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; Endothelial cell; Endothelial progenitor cell; Scleroderma; Systemic sclerosis; Vascular repair; Vasculogenesis

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; CAPILLARY; ENDOTHELIUM; HUMAN; NEOVASCULARIZATION (PATHOLOGY); ORGANOGENESIS; PATHOLOGY; PRENATAL DEVELOPMENT; REVIEW; SYSTEMIC SCLEROSIS; EMBRYOLOGY; SCLERODERMA, SYSTEMIC;

ANIMALS; BIOLOGICAL MARKERS; CAPILLARIES; ENDOTHELIUM; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOGENESIS; SCLERODERMA, SYSTEMIC;

EID: 77955142127     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01027.x     Document Type: Review

References (126)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007, 117:557-67.
2. Jimenez SA, Derk CT. Following the molecular pathways towards an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med. 2004, 140:37-50.
3. Guiducci S, Giacomelli R, Matucci-Cerinic M. Vascular complications of scleroderma. Autoimmun Rev. 2007, 6:520-3.
4. Kahaleh MB. Vascular involvement in systemic sclerosis. Clin Exp Rheumatol. 2004, 22:S19-23.
5. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am. 1996, 22:675-94.
6. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther. 2007, 9:S3.
7. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975, 4:351-68.
8. Trotta F, Biagini G, Cenacchi G. Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol. 1984, 2:209-15.
9. Ibba-Manneschi L, Del Rosso A, Milia AF. Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. Rheumatology. 2005, 44:607-13.
10. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine. 1980, 59:393-408.
11. Al-Sabbagh MR, Steen VD, Zee BC. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol. 1989, 16:1038-42.
12. Cool CD, Kennedy D, Voelkel NF. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997, 28:434-42.
13. Penn H, Howie AJ, Kingdon EJ. Scleroderma renal crisis: patient characteristics and long-term outcomes. Q J Med. 2007, 100:485-94.
14. Rhew EY, Barr WG. Scleroderma renal crises: new insights and developments. Curr Rheumatol Rep. 2004, 6:129-36.
15. Cutolo M, Grassi W, Matucci-Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum. 2003, 48:3023-30.
16. Maricq HR. Wide-field capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum. 1981, 24:1159-65.
17. Sulli A, Secchi ME, Pizzorni C. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis. 2008, 67:885-7.
18. Kahaleh B. Progress in research into systemic sclerosis. Lancet. 2004, 364:561-2.
19. Distler O, Distler JH, Scheid A. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004, 95:109-16.
20. Distler JH, Beyer C, Schett G. Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum. 2009, 60:3168-79.
21. Cipriani P, Guiducci S, Miniati I. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007, 56:1994-2004.
22. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005, 438:932-6.
23. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1:27-31.
24. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000, 6:389-95.
25. Distler J, Hirth A, Kurowska-Stolarska M. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003, 47:149-61.
26. Asahara T, Murohara T, Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997, 275:964-7.
27. Shi Q, Rafii S, Wu MH. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998, 92:362-7.
28. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004, 95:343-53.
29. Tateishi-Yuyama E, Matsubara H, Murohara T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002, 360:427-35.
30. Stamm C, Westphal B, Kleine HD. Autologous bone-marrow stem cell transplantation for myocardial regeneration. Lancet. 2003, 361:45-6.
31. Fleming JN, Nash RA, McLeod DO. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype. PLoS ONE. 2008, 3:e1452.
32. Miniati I, Guiducci S, Conforti ML. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis. 2009, 68:94-8.
33. Nevskaya T, Ananieva L, Bykovskaia S. Autologous progenitor cell implantation as a novel therapeutic intervention for ischemic digits in systemic sclerosis. Rheumatology. 2009, 48:61-4.
34. Krenning G, van Luyn MJ, Harmsen MC. Endothelial progenitor cell-based neovascularization: implications for therapy. Trends Mol Med. 2009, 15:180-9.
35. Deschaseaux F, Selmani Z, Falcoz PE. Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors. Eur J Pharmacol. 2007, 562:111-8.
36. Hur J, Yoon CH, Kim HS. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004, 24:288-93.
37. Prescott RJ, Freemont AJ, Jones CJ. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992, 166:255-63.
38. Sgonc R, Gruschwitz MS, Dietrich H. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996, 98:785-92.
39. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am. 2008, 34:57-71.
40. Nietert PJ, Silver RM. Systemic sclerosis: environmental and occupational risk factors. Curr Opin Rheumatol. 2000, 12:520-6.
41. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998, 41:10-5.
42. Lunardi C, Bason C, Navone R. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med. 2000, 6:1183-6.
43. Renaudineau Y, Revelen R, Levy Y. Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol. 1999, 6:156-60.
44. Pignone A, Scaletti C, Matucci-Cerinic M. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol. 1998, 16:527-32.
45. Sgonc R, Gruschwitz MS, Boeck G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000, 43:2550-62.
46. Gabrielli A, Svegliati S, Moroncini G. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol. 2008, 30:329-37.
47. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med. 1997, 185:71-9.
48. Blake DR, Winyard P, Scott DG. Endothelial cell cytotoxicity in inflammatory vascular diseases: the possible role of oxidised lipoproteins. Ann Rheum Dis. 1985, 44:176-82.
49. Matucci-Cerinic M, Valentini G, Sorano GG. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum. 2003, 32:285-95.
50. Koch AE, Kronfeld-Harrington LB, Szekanecz Z. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology. 1993, 61:239-46.
51. Sollberg S, Peltonen J, Uitto J. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum. 1992, 35:290-8.
52. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol. 2005, 24:111-6.
53. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol. 1999, 11:503-7.
54. Manetti M, Neumann E, Müller A. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum. 2008, 58:2866-73.
55. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006, 2:679-85.
56. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2007, 19:574-9.
57. Kahaleh MB, Osborn I, LeRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med. 1982, 96:610-3.
58. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther. 2007, 9:S2.
59. Hummers LK. Biomarkers of vascular disease in scleroderma. Rheumatology. 2008, 47:v21-2.
60. Denton CP, Bickerstaff MC, Shiwen X. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol. 1995, 34:1048-54.
61. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981, 94:482-4.
62. Wigley FM. Vascular disease in scleroderma. Clin Rev Allerg Immunol. 2009, 36:150-75.
63. Guiducci S, Distler JH, Jungel A. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum. 2008, 58:2845-53.
64. Del Papa N, Colombo G, Fracchiolla N. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum. 2004, 50:1296-304.
65. Konttinen YT, Mackiewicz Z, Ruuttila P. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol. 2003, 22:196-202.
66. Mulligan-Kehoe MJ, Drinane MC, Mollmark J. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 2007, 56:3448-58.
67. Ribatti D, Crivellato E. Immune cells and angiogenesis. J Cell Mol Med. 2009, 13:2822-33.
68. Kaminski MJ, Majewski S, Jablonska S. Lowered angiogenic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). J Invest Dermatol. 1984, 82:239-43.
69. Koch AE, Litvak MA, Burrows JC. Decreased monocyte-mediated angiogenesis in scleroderma. Clin Immunol Immunopathol. 1992, 64:153-60.
70. Kahaleh MB, DeLustro F, Bock W. Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. Clin Immunol Immunopathol. 1986, 39:242-55.
71. Majewski S, Skopinska-Rozewska E, Jablonska S. Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum. 1985, 28:1133-9.
72. Marczak M, Majewski S, Skopinska-Rozewska E. Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspension from patients with systemic scleroderma. J Invest Dermatol. 1986, 86:355-8.
73. Ribatti D, Cantatore FP, Vacca A. Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin Rheumatol. 1998, 17:115-20.
74. Distler O, Del Rosso A, Giacomelli R. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002, 4:R11.
75. Distler O, Pap T, Kowal-Bielecka O. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001, 44:2665-78.
76. Cipriani P, Milia AF, Liakouli V. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum. 2006, 54:3022-33.
77. Hummers LK, Hall A, Wigley FM. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol. 2009, 36:576-82.
78. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005, 9:777-94.
79. Mackiewicz Z, Sukura A, Povilenaite D. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002, 20:641-6.
80. Davies CA, Jeziorska M, Freemont AJ. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006, 37:190-7.
81. Allanore Y, Borderie D, Lemaréchal H. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther. 2004, 6:R309-14.
82. Choi JJ, Min DJ, Cho ML. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol. 2003, 30:1529-33.
83. Ibba-Manneschi L, Manetti M, Milia AF. Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings. Ann Rheum Dis. 2010, 69:458-61.
84. Dor Y, Djonov V, Abramovitch R. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002, 21:1939-47.
85. D'Alessio S, Fibbi G, Cinelli M. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004, 50:3275-85.
86. Beyer C, Schett G, Gay S. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009, 11:220.
87. Hebbar M, Peyrat JP, Hornez L. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000, 43:889-93.
88. Macko RF, Gelber AC, Young BA. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol. 2002, 29:2565-70.
89. Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E. Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis - association with pulmonary involvement. Clin Exp Rheumatol. 2006, 24:508-13.
90. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm. 2005, 3:144-9.
91. Italiano JE, Richardson JL, Paltel-Hett S. Angiogenesis is regulated by a novel mechanism: pro- and anti-angiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008, 111:1227-33.
92. Klement GL, Yip TT, Cassiola F. Platelets actively sequester angiogenesis regulators. Blood. 2009, 113:2835-42.
93. Solanilla A, Villeneuve J, Auguste P. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology. 2009, 48:1036-44.
94. Giusti B, Serratì S, Margheri F. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 2005, 52:3618-28.
95. Giusti B, Fibbi G, Margheri F. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther. 2006, 8:R115.
96. Emanueli C, Minasi A, Zacheo A. Local delivery of Human Tissue Kallikrein Gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001, 103:125-32.
97. Mahabeer R, Bhoola KD. Kallikrein and kinin receptor genes. Pharmacol Ther. 2000, 88:77-89.
98. Del Rosso A, Distler O, Milia AF. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis. 2005, 64:382-7.
99. Milia AF, Del Rosso A, Pacini A. Differential expression of tissue kallikrein in the skin of systemic sclerosis. Histol Histopathol. 2005, 20:415-22.
100. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis. 1999, 3:15-32.
101. Kroon ME, Koolwijk P, van Goor H. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol. 1999, 154:1731-42.
102. Fibbi G, Caldini R, Chevanne M. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest. 1998, 78:1109-19.
103. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci. 2006, 63:1028-37.
104. Serratì S, Cinelli M, Margheri F. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006, 210:240-8.
105. Margheri F, Manetti M, Serratì S. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006, 54:3926-38.
106. Salvucci O, Yao L, Villalba S. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002, 99:2703-11.
107. Salcedo R, Wasserman K, Young HA. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol. 1999, 154:1125-35.
108. Mohle R, Bautz F, Rafii S. The chemokine receptor CXCR4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998, 91:4523-30.
109. Manetti M, Liakouli V, Fatini C. Association between a stromal cell-derived factor 1 (SDF-/XCL12) gene polymorphism and microvascular disease in systemic sclerosis. Ann Rheum Dis. 2009, 68:408-11.
110. Allanore Y, Wipff J, Kahan A. Genetic basis for systemic sclerosis. Joint Bone Spine. 2007, 74:577-83.
111. Wang Y, Kahaleh B. Epigenetic repression of the bone morphogenetic protein type II receptor expression in scleroderma endothelial cells: a possible basis for enhanced SSc endothelial vulnerability to apoptosis. Arthritis Rheum. 2008, 58:S928.
112. Kuwana M, Okazaki Y, Yasuoka H. Defective vasculogenesis in systemic sclerosis. Lancet. 2004, 364:603-10.
113. Zhu S, Evans S, Yan B. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation. 2008, 118:2156-65.
114. Nevskaya T, Bykovskaia S, Lyssuk E. Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol. 2008, 26:421-9.
115. Allanore Y, Batteux F, Avouac J. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol. 2007, 25:60-6.
116. Avouac J, Juin F, Wipff J. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis. 2008, 67:1455-60.
117. Del Papa N, Quirici N, Soligo D. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006, 54:2605-15.
118. Kuwana M, Kaburaki J, Okazaki Y. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 2006, 54:1946-51.
119. Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol. 2009, 19:530-5.
120. Del Papa N, Cortiana M, Vitali C. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol. 2008, 35:1323-8.
121. Avouac J, Wipff J, Goldman O. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum. 2008, 58:3550-61.
122. Hao X, Silva EA, Mansson-Broberg A. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res. 2007, 75:178-85.
123. Chen RR, Silva EA, Yuen WW. Integrated approach to designing growth factor delivery systems. FASEB J. 2007, 21:3896-903.
124. Zisch AH, Lutolf MP, Ehrbar M. Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. FASEB J. 2003, 17:2260-2.
125. Popa ER, van der Strate BW, Brouwer LA. Dependence of neovascularization mechanisms on the molecular microenvironment. Tissue Eng. 2007, 13:2913-21.
126. Maurer B, Busch N, Jüngel A. Transcription factor Fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation. 2009, 120:2367-76.